Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. 1996

H Urata, and H Nishimura, and D Ganten, and K Arakawa
Max-Delbrück-Centre for Molecular Medicine (MDC)., Department of Hypertension Research, Berlin-Buch, Germany.

The tissue renin-angiotensin system plays an integral role in the homeostasis of blood pressure and in the pathogenesis of cardiovascular remodeling. These effects are primarily mediated through the paracrine and autocrine actions of locally produced angiotensin II (A II). It is generally accepted that the conversion of angiotension I to A II is mainly due to angiotensin-converting enzyme (ACE). However, there are several in vitro and in vivo reports of ACE-independent synthesis of A II in hypoxic and ischemic heart and blood vessels, which may also contribute to cardiovascular pathology. The differential cellular and regional expression of ACE and chymase in the human heart and blood vessels suggests distinct pathophysiologic roles for these two A II-forming enzymes. The study of different pathways involved in tissue A II formation, including that of ACE- and chymase-independent enzymes, will clarify their respective contribution to the pathophysiologic changes in cardiovascular diseases, and help in planning a more comprehensive clinical strategy. This report reviews the properties of human heart chymase, an A II-forming serine proteinase, and compares it with those of ACE.

UI MeSH Term Description Entries
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012697 Serine Endopeptidases Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis. Serine Endopeptidase,Endopeptidase, Serine,Endopeptidases, Serine
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D053818 Chymases A family of neutral serine proteases with CHYMOTRYPSIN-like activity. Chymases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation. Chymase,Chymase-1,Chymotrypsin-Like Protease,Chymotrypsin-Like Proteases,Chymase 1,Chymotrypsin Like Protease,Chymotrypsin Like Proteases

Related Publications

H Urata, and H Nishimura, and D Ganten, and K Arakawa
September 2003, International journal of oncology,
H Urata, and H Nishimura, and D Ganten, and K Arakawa
December 1997, Kidney international. Supplement,
H Urata, and H Nishimura, and D Ganten, and K Arakawa
November 1993, European heart journal,
H Urata, and H Nishimura, and D Ganten, and K Arakawa
January 1998, Biological research,
H Urata, and H Nishimura, and D Ganten, and K Arakawa
January 2004, Ophthalmic research,
H Urata, and H Nishimura, and D Ganten, and K Arakawa
April 1985, Clinica chimica acta; international journal of clinical chemistry,
H Urata, and H Nishimura, and D Ganten, and K Arakawa
February 2009, Hypertension (Dallas, Tex. : 1979),
H Urata, and H Nishimura, and D Ganten, and K Arakawa
March 1980, Experimental eye research,
H Urata, and H Nishimura, and D Ganten, and K Arakawa
June 1983, Laboratory investigation; a journal of technical methods and pathology,
H Urata, and H Nishimura, and D Ganten, and K Arakawa
January 2000, Terapevticheskii arkhiv,
Copied contents to your clipboard!